High-dose valsartan for prevention of in-stent restenosis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1637, 2008-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of Efficacy of Low- (80 mg/day) and High- (160-320 mg/day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions

By Peters Stefan

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 83-87

Adis International

Access to resources Recommend Favorite

Rapamycin can Inhibit the Development of Chlamydia pneumoniae, which Might Partly Contribute to the Prevention of In-stent Restenosis

By Yan Ying Silvennoinen-Kassinen Sylvi Leinonen Maija Saikku Pekka

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 3, 2010-06 ,pp. : 189-195

Springer Publishing Company

Access to resources Recommend Favorite

Valsartan + high-dose HCTZ for hypertension

Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Rosiglitazone reduces in-stent restenosis in patients with diabetes

Inpharma, Vol. 1, Iss. 1462, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Candesartan cilexetil may reduce in-stent restenosis

Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite